Drug Discovery

#AI / data analytics / healthtech / informatics #Business #Chemical engineering #Chemistry #Drug discovery #RNA

Intelligent mobile robot scientist can carry out experiments by itself

10 July 2020 Image: Brett Jordan The robot scientist, the first of its kind, makes its own decisions about which chemistry experiments to perform next, and has already discovered a new catalyst. It has humanoid dimensions and works in a standard laboratory, using instruments much like a human… Read More

#News

#Cell therapy #Clinical specialities #Clinical trials #Drug development #Immunology #Microbiology #Preclinical #RNA #Stem cells #System biology

Researchers find promising therapy to fight epidemic of liver disease

9 July 2020 Image: Science in HD So far there are no approved drugs for Non-Alcoholic Fatty Liver Disease In an effort to combat a growing worldwide epidemic of Nonalcoholic Fatty Liver Disease (NAFLD), scientists have discovered a new target and a new therapy that has shown promising… Read More

#News

#AI / data analytics / healthtech / informatics #Biochemistry #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Regulatory #RNA #Therapeutics

Cost-effective drug discovery: How this AI system aims to assist

Aigenpulse has released an intelligence platform designed to speed up the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence (AI) and machine learning tools to deliver advanced analytics to underpin scientific decision making. Aigenpulse has built the data-agnostic platform for importing, integrating, processing, linking,… Read More

#Covid-19 #News

#Business #Drug discovery #Gene editing #Genetics / genomes #RNA #Target validation

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines

9 July 2020 Horizon Discovery Group has introduced stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively. The cell lines are optimised to work alongside Horizon’s Edit-R predesigned synthetic single guide RNA (sgRNA) and CRISPRa guide RNA, offering researchers a… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Business #Drug development #Drug discovery #Imaging #Lead discovery #RNA #Screening #Therapeutics

Nanoimaging Services expands with East Coast facility

8 July 2020 Image: Osman Rana NanoImaging Services (NIS), has opened a facility in Boston. NIS is expanding with services and locations to support its growing customer base requiring cryoEM for drug discovery and vaccine development applications. “For more than a decade, we’ve applied our scientific leadership and… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cell culture #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Lead discovery #Lead optimisation #Medicinal chemistry #System biology

How drug discovery software is inspiring US high-school students

Optibrium and the North Carolina School of Science and Mathematics (NCSSM), are celebrating five years of an education support collaboration. As part of this specialist science and technology summer school initiative, Optibrium provides free access to StarDrop, Optibrium’s software for small molecule design, optimisation and data analysis. This… Read More

#Covid-19 #News

#Academic #Biomarkers #Business #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Panthera and Rutherford Health launch oncology clinical trial network

7 July 2020 Rutherford’s independent network currently consists of four cancer treatment centres in Newport, Reading, Bedlington and Liverpool. It will draw patients from all over the UK offering pharma and CROs access to patients through more than 170 referring oncologists. Each of the Rutherford Cancer Centres has… Read More

#News

#AI / data analytics / healthtech / informatics #Analysis #Business #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #Metabolomics #Microbiome #Oncology #Therapeutics

Genomics contract research organisation rebrands as Eremid Research Services

6 July 2020 Image: Science in HD Eremid Research Services is the new name for the commercial arm of research organisation, DHMRI. Eremid continues to specialise in the provision of genomics, metabolomics, NMR and vivarium research services, offering expertise in areas including human health, food & nutrition, and AgBiotech. The company offers a… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #Molecular medicine #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Cell ‘membrane on a chip’ could speed up screening of drug candidates for COVID-19

Researchers have developed a human cell ‘membrane on a chip’ that allows continuous monitoring of how drugs and infectious agents interact with our cells. It may soon be used to test potential drug candidates for COVID-19. The researchers, from the University of Cambridge, Cornell University and Stanford University,… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Could marine alga be a remedy against infections and skin cancer?

Share Share Tweet Email Could marine alga be a remedy against infections and skin cancer? Could marine alga be a remedy against infections and skin cancer? 6 July 2020 Image: Shane Stagner Marine organisms… Read More

#News

#Clinical specialities #Clinical trials #Drug discovery #Imaging

4D pharma enrolment for phase II study of MRx-4DP0004 for COVID-19 patients

4D pharma has announced that its phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients hospitalised with COVID-19 is now open to enrolment. Dosing of the first patients is expected shortly. The phase II randomised, double-blind, placebo-controlled trial is enrolling up to 90 patients admitted to hospital… Read More

#Covid-19 #News

#Analysis #Assay development optimisation & technology #Drug discovery #Protein chemistry / Proteomics #Sequencing #Target validation

Proteomics on NGS: Why this new launch could be a game changer

6 July 2020 Image: Science in HD Olink Proteomics’ Olink Explore 1536 combines the company’s proximity extension assay (PEA) high-multiplex immunoassay technology with next-generation sequencing (NGS) readout on the Illumina NovaSeq platform. Olink Explore 1536 has several features designed to overcome significant limitations in other proteomic technologies, including… Read More

#News

#Clinical specialities #Drug development #Drug discovery #Regulatory #RNA

FDA approves ViiV Healthcare’s Rukobia for HIV in adults

3 July 2020 Image: Halacious The FDA has approved ViiV Healthcare’s Rukobia (fostemsavir), 600mg extended-release tablets for adults who cannot be treated with other therapies due to resistance, intolerance or safety considerations. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in… Read More

#News

#AI / data analytics / healthtech / informatics #Business #Drug development #Drug discovery #Genomics #High throughput screening #Screening #Sequencing #Therapeutics

My Personal Therapeutics and Pentavere scoop funding for lung cancer digital therapeutics

3 July 2020 Image: Japeth Mast My Personal Therapeutics and Pentavere Research Group, have achieved EUREKA Collaborative R&D: AI and Quantum Technologies Competition success for their project Utilisation of AI to develop Personalised Treatment Plans for cancer. Funding totalling £792,000 is co-funded by the UK’s innovation agency, Innovate… Read More

#News

#Analysis #Clinical specialities #Clinical trials #Drug discovery #Imaging

Sanofi and Regeneron stop Kevzara COVID-19 trial in US

Sanofi and Regeneron Pharmaceuticals have announced that the US Phase III trial of rheumatoid arthritis drug Kevzara (sarilumab) in COVID-19 patients requiring mechanical ventilation did not meet its main goals. Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400mg who were… Read More

#Covid-19 #News